ImaginAb

Activities: Research & Development Analysis

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Pharma turns to CD8 in vivo imaging to predict response to immunotherapy

Improving the success rates of immunotherapy drugs has long been a difficult challenge. But finding ways to accurately measure the presence of CD8+ T cells could provide more certainty, according to pioneering US biotech ImaginAb
Regulatory

ImaginAb announces supply agreement with Genmab

The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development

A new approach to molecular imaging in cancer patients

A variety of different imaging approaches, spanning molecular to whole-body scans, have contributed greatly to our understanding of the conditions required for an effective anticancer immune response, reports Ian Wilson, CEO, ImaginAb
Subscribe now